Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;1(5):351-7.
doi: 10.1177/2050640613501507.

Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database

Tobias Eggert  1 , Katherine A McGlynn  2 , Austin Duffy  3 , Michael P Manns  4 , Tim F Greten  3 , Sean F Altekruse  5
Affiliations

Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database

Tobias Eggert et al. United European Gastroenterol J. 2013 Oct.

Abstract

Objective: Epidemiological and clinical information on fibrolamellar hepatocellular carcinoma (fHCC) is scarce. We performed a Surveillance, Epidemiology and End Results (SEER) database analysis with the aim of collecting information to better understand the biology and clinical aspects of this rare disease.

Design: Incidence trends, race- and age-specific rates, tumor size, first course surgery and five-year relative survival of 191 US cases (SEER) diagnosed with fHCC during 2000-2010 were compared to cases with hepatocellular carcinoma (HCC), HCC-not otherwise specified (HCC-NOS) and other HCC-types.

Results: While HCC-NOS incidence rates increased by 5.2% annually from 2000-2008 (p < 0.05) before leveling, the 1.3% change in fHCC incidence was not statistically significant. The rates of fHCC were similar across ethnic groups while HCC-NOS incidence rates were higher among non-whites. Although 16% of fHCC patients had primary tumors ≤5 cm compared to 37% of HCC-NOS cases five-year survival was better among fHCC (34%) than HCC-NOS cases (16%). Fibrolamellar HCC cases of 0-39 years of age were more likely to receive radiofrequency ablation, transplant or resection than HCC-NOS cases of that age. Survival was similar among fibrolamellar and HCC-NOS cases receiving surgery.

Conclusion: In this largest case series, fibrolamellar and HCC-NOS age- and race-specific incidence rates and time trends differed. Despite larger tumor size than HCC-NOS cases fibrolamellar cases received surgery more often and had better survival rates. Differences in co-morbidity may influence treatment. Studies of fHCC biology, including by age, are recommended.

Keywords: Liver cancer; epidemiology; fibrolamellar.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Age-adjusted hepatocellular carcinoma (HCC) incidence trends by histologic type, Surveillance, Epidemiology, and End Results (SEER) 18 registries, 2000–2010. *indicates slope of regression line is statistically different from zero, p < 0.05. APC: annual percent change; HCC-NOS: HCC-not otherwise specified.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer. About CANCERMondial, Available at: www-dep.iarc.fr (accessed 6 May 2013)
    1. Parkin DM, Bray F, Ferlay J, et al. . Global cancer statistics. 2002. CA Cancer J Clin 2005; 55: 74–108 - PubMed
    1. Fritz A, Percy C, Jack A, et al. (eds) International classification of diseases for oncology. 3rd ed. Geneva: World Health Organzation, 2010.
    1. McDermott WV, Cady B, Georgi B, et al. . Primary cancer of the liver. Evaluation, treatment, and prognosis. Arch Surg 1989; 124: 552–554. discussion: 554–555) - PubMed
    1. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004; 39: 798–803 - PubMed